Tuesday, December 1, 2009

GBP Health/Biotech 11-30-2009

GBP Health / Biotech News 11-30-2009 <http://dustedoff.blogspot.com/2009/11/gbp-health-biotech-news-11-23-2009.html>
Since August, 2005, this news digest has been a complimentary service of GBP Capital, a private equity firm investing in early to mid-stage life science companies. Please see www.gbpcap.com <http://www.gbpcap.com/> for more information. The digest is published roughly biweekly. If you have colleagues who would be interested in receiving this digest, they can be added to the list at: www.gbpcap.com <http://www.gbpcap.com/> . To search the archive of all published digests please visit: www.gpbcap.com/ja/news/news-digest-archive.html <http://www.gpbcap.com/ja/news/news-digest-archive.html>



Source - EurekAlert – Biology:


Public Release: 30-Nov-2009
Journal of Biology
A reductionist approach to HIV research <http://www.eurekalert.org/pub_releases/2009-11/bc-ara113009.php>
A major obstacle to HIV research is the virus's exquisite specialisation for its human host -- meaning that scientists' traditional tools, like the humble lab mouse, can deliver only limited information. Now, a team of researchers writing in BioMed Central's open access Journal of Biology have made an ingenious assault on this problem by creating a mouse that has key features of HIV infection without being infected with HIV.
Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com <mailto:graeme.baldwin@biomedcentral.com>
44-020-319-22165
BioMed Central <http://www.biomedcentral.com/>

Public Release: 30-Nov-2009
Nature Materials
First metallic nanoparticles resistant to extreme heat <http://www.news.pitt.edu/m/FMPro?-db=ma&-lay=a&-format=d.html&id=3918&-Find>
A University of Pittsburgh team overcame a major hurdle plaguing the development of nanomaterials such as those that could lead to more efficient catalysts used to produce hydrogen and render car exhaust less toxic. The researchers reported Nov. 29 in Nature Materials the first demonstration of high-temperature stability in metallic nanoparticles, the vaunted next-generation materials hampered by a vulnerability to extreme heat.
Contact: Morgan Kelly
mekelly@pitt.edu <mailto:mekelly@pitt.edu>
412-624-4356
University of Pittsburgh <http://www.pitt.edu/>

Public Release: 30-Nov-2009
Multiple Sclerosis
Panel of multiple sclerosis experts provides best practice treatment recommendations for Tysabri <http://www.eurekalert.org/pub_releases/2009-11/gh-pom112509.php>
Best-practice recommendations for the selection and management of patients with multiple sclerosis who may benefit from, or are receiving treatment with, Tysabri (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis. The panel provided recommendations focusing on appropriate patient selection and patient management. The recommendations recognize the significant efficacy of Tysabri and the need to adequately treat patients who exhibit continued disease activity.
Biogen Idec, Elan Corp., plc.
Contact: Shannon Altimari
shannon.altimari@biogenidec.com <mailto:shannon.altimari@biogenidec.com>
GCI Health

Public Release: 27-Nov-2009
Deutsches Ärzteblatt International
Does a placebo gene exist? <http://www.eurekalert.org/pub_releases/2009-11/dai-dap112709.php>
A short time ago, Swedish scientists published a paper suggesting the existence of a genetic disposition to respond to placebo, thus giving rise to debate in the media about a possible "placebo gene." In the current issue of Deutsches Ärzteblatt International, Matthias Breidert and Karl Hofbauer summarize the most recent data about placebos.
Contact: E. Bartholomaeus
49-223-470-11133
Deutsches Aerzteblatt International <http://www.aerzteblatt-international.de/int/>

Public Release: 26-Nov-2009
Science
First-ever blueprint of a minimal cell is more complex than expected <http://www.eurekalert.org/pub_releases/2009-11/embl-fbo112409.php>
In three papers published back-to-back today in Science, scientists in a partnership between the European Molecular Biology Laboratory in Heidelberg, Germany, and the Centre de Regulacio Genòmica in Barcelona, Spain, provide the first comprehensive picture of a minimal cell, based on an extensive quantitative study of the biology of the bacterium that causes atypical pneumonia, Mycoplasma pneumoniae. The study uncovers fascinating novelties relevant to bacterial biology and shows that even the simplest of cells is more complex than expected.
Contact: Sonia Furtado
sonia.furtado@embl.de <mailto:sonia.furtado@embl.de>
European Molecular Biology Laboratory <http://www.embl.org/>

Public Release: 26-Nov-2009
Science
Knockouts in human cells point to pathogenic targets <http://www.eurekalert.org/pub_releases/2009-11/wifb-kih112309.php>
Whitehead researchers have developed a new approach for genetics in human cells and used this technique to identify specific genes and proteins required for pathogens. With the ability to generate knockout cells for most human genes, the authors were able to find genes used by pathogens to enter and kill human cells. The identification of such factors could aid the future development of new therapeutics to combat infectious disease.
Fundaaoo para a Ciencia ea Tecnologia, Kimmel Foundation

Contact: Nicole Giese
giese@wi.mit.edu <mailto:giese@wi.mit.edu>
617-258-6851
Whitehead Institute for Biomedical Research <http://www.wi.mit.edu/index.html>

Public Release: 25-Nov-2009
Nature Medicine
New genetic cause of cardiac failure discovered <http://www.klinikum.uni-heidelberg.de/ShowSingleNews.7870.0.html?&cHash=dc675b55a9&tx_ttnews%5bbackPid%5d=7868&tx_ttnews%5bpS%5d=1259156914&tx_ttnews%5btt_news%5d=4836>
Over the course of a lifetime, the heart pumps some 250 million liters of blood through the body. In the order to do this, the muscle fibers of the heart have to be extremely durable. The research group headed by Dr. Wolfgang Rottbauer, vice chair of the department of medicine III at Heidelberg University Hospital, has discovered a protein that is responsible for the stability of the smallest muscular unit, the sarcomere.
Contact: Dr. Wolfgang Rottbauer
wolfgang.rottbauer@med.uni-heidelberg.de <mailto:wolfgang.rottbauer@med.uni-heidelberg.de>
49-622-156-38851
University Hospital Heidelberg <http://www.klinikum.uni-heidelberg.de/>

Public Release: 25-Nov-2009
Science Translational Medicine
Implant-based cancer vaccine is first to eliminate tumors in mice <http://www.eurekalert.org/pub_releases/2009-11/hu-icv112009.php>
A cancer vaccine carried into the body on a carefully engineered, fingernail-sized implant is the first to successfully eliminate tumors in mammals. The new approach, pioneered by bioengineers and immunologists at Harvard University, uses plastic disks impregnated with tumor-specific antigens and implanted under the skin to reprogram the mammalian immune system to attack tumors.
National Institutes of Health, Harvard University, InCytu Inc.
Contact: Steve Bradt
steve_bradt@harvard.edu <mailto:steve_bradt@harvard.edu>
617-496-8070
Harvard University <http://www.harvard.edu/>

Public Release: 24-Nov-2009
A coating for life <http://www.aftau.org/site/News2?page=NewsArticle&id=11029>
Prof. Meital Zilberman of Tel Aviv University has developed a new patent-pending dissolvable fiber platform that can be used to coat both metal stents, which are currently available, and biodegradable stents now in development.
Contact: George Hunka
ghunka@aftau.org <mailto:ghunka@aftau.org>
212-742-9070
American Friends of Tel Aviv University <http://www.aftau.org/>

Public Release: 24-Nov-2009
New device enables early detection of cancerous skin tumors -- Ben Gurion U. <http://www.eurekalert.org/pub_releases/2009-11/aabu-nde112409.php>
Researchers at Ben-Gurion University of the Negev are developing a new device that detects cancerous skin tumors, including melanomas that aren't visible to the naked eye. The OSPI instrument (Optical Spectro-Polarimetric Imaging) revealed new textures of lesions that have never been seen before. Dermatologists and plastic surgeons typically diagnose skin tumors by their appearance with the naked eye and only rarely using a dermatoscope -- a magnifying tool that allows tumors to be examined in detail.
Contact: Andrew Lavin
andrewlavin@alavin.com <mailto:andrewlavin@alavin.com>
516-944-4486
American Associates, Ben-Gurion University of the Negev <http://www.aabgu.org/>

Public Release: 24-Nov-2009
Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage <http://www.eurekalert.org/pub_releases/2009-11/uog-gie112409.php>
The gene in question is a suicide gene, called "gene E," which leads to the death of tumor cells derived from breast, lung and colon cancer, and prevents their growth. Chemotherapy, radiotherapy and surgery show "limited" results in advanced stages of cancer, so the kind of gene therapy proposed by the scientists of the UGR is a huge breakthrough in cancer treatment.
Contact: Antonia Aranega Jimenez
anarosarama@ugr.es <mailto:anarosarama@ugr.es>
34-958-243-534
University of Granada <http://www.ugr.es/>

Source - Science Daily:
Please note: Due to the format restrictions of Science Daily articles, you must click on the URL (web address) below the article summary, rather than the article title.

Control of Blood Clotting by Platelets Described; Provides Medical Promise <http://www.sciencedaily.com/releases/2009/11/091123212551.htm>
November 26, 2009
— Cell fragments called platelets are essential to promote blood clotting. Researchers have now discovered novel molecular interactions at the surface of platelets that control blood ...
http://www.sciencedaily.com/releases/2009/11/091123212551.htm

New Tools for Prediction of Disease Progression in Acute Childhood Leukemia <http://www.sciencedaily.com/releases/2009/11/091127124219.htm>
November 30, 2009
— Researchers have devised powerful new tools for typing cells from children with acute lymphatic leukemia and for prediction of how children with leukemia will respond to ...
http://www.sciencedaily.com/releases/2009/11/091127124219.htm <http://www.sciencedaily.com/releases/2009/11/091127124219.htm>

Stents Can Be Coated With Dissolvable Drug-Eluting Fibers <http://www.sciencedaily.com/releases/2009/11/091124113613.htm>
November 30, 2009
— Scientists have developed a new patent-pending dissolvable fiber platform that can be used to coat both metal stents, which are currently available, and biodegradable stents now in ...
http://www.sciencedaily.com/releases/2009/11/091124113613.htm <http://www.sciencedaily.com/releases/2009/11/091124113613.htm>

Invention Will Help Speed Development of Drug Treatments for Heart Failure <http://www.sciencedaily.com/releases/2009/11/091123114801.htm>
November 26, 2009
— New research has led to the invention of technology to more rapidly identify compounds for the treatment of heart ...
http://www.sciencedaily.com/releases/2009/11/091123114801.htm <http://www.sciencedaily.com/releases/2009/11/091123114801.htm>

First Live Targeting of Tumors With RNA-Based Technology <http://www.sciencedaily.com/releases/2009/11/091130084810.htm> November 30, 2009 — Researchers have devised a way they might deliver the right therapy directly to tumors using special molecules, called aptamers, which specifically bind to living tumor tissue. They screened a large ...
http://www.sciencedaily.com/releases/2009/11/091130084810.htm <http://www.sciencedaily.com/releases/2009/11/091130084810.htm>

New Findings Suggest Strategy to Help Generate HIV-Neutralizing Antibodies <http://www.sciencedaily.com/releases/2009/11/091119193938.htm>
November 29, 2009
— New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new ...
http://www.sciencedaily.com/releases/2009/11/091119193938.htm <http://www.sciencedaily.com/releases/2009/11/091119193938.htm>

How HIV Is Assembled and Released from Infected Cells <http://www.sciencedaily.com/releases/2009/11/091112113423.htm>
November 29, 2009
— The HIV/AIDS virus continues to ravage populations worldwide. Using a novel combination of optical techniques, researchers visualize how virus particles assemble and are released from infected cells ...
http://www.sciencedaily.com/releases/2009/11/091112113423.htm <http://www.sciencedaily.com/releases/2009/11/091112113423.htm>

'Glow-in-the-Dark' Red Blood Cells Made from Human Stem Cells <http://www.sciencedaily.com/releases/2009/08/090824115915.htm>
November 29, 2009
— Stem cell scientists have modified a human embryonic stem cell (hESC) line to glow red when the stem cells become red blood cells. The modified hESC line, ErythRED, represents a major step forward to ...
http://www.sciencedaily.com/releases/2009/08/090824115915.htm <http://www.sciencedaily.com/releases/2009/08/090824115915.htm>

Diabetes Cases to Double and Costs to Triple by 2034 <http://www.sciencedaily.com/releases/2009/11/091127101038.htm>
November 27, 2009
— In the next 25 years, the number of Americans living with diabetes will double and spending on diabetes will triple, rising from $113 billion to $336 billion. This will add to the existing ...
http://www.sciencedaily.com/releases/2009/11/091127101038.htm <http://www.sciencedaily.com/releases/2009/11/091127101038.htm>

New Cause for Alzheimer's Disease? <http://www.sciencedaily.com/releases/2009/11/091125151814.htm>
November 27, 2009
— Scientists have discovered that a precursor to nerve growth factor (pro-NGF) may play a pathogenic role in Alzheimer's ...
http://www.sciencedaily.com/releases/2009/11/091125151814.htm <http://www.sciencedaily.com/releases/2009/11/091125151814.htm>

Stem Cells Heal Lungs of Newborn Animals: May Lead to New Treatments for Lungs of Premature Babies <http://www.sciencedaily.com/releases/2009/11/091126124140.htm>
November 27, 2009
— Scientists have demonstrated that stem cells protect and repair the lungs of newborn rats. The study finds that rats treated with stem cells ran twice as far, and had better survival rates. ...
http://www.sciencedaily.com/releases/2009/11/091126124140.htm <http://www.sciencedaily.com/releases/2009/11/091126124140.htm>

Implant-Based Cancer Vaccine Is First to Eliminate Tumors in Mice <http://www.sciencedaily.com/releases/2009/11/091125145819.htm>
November 26, 2009
— A cancer vaccine carried into the body on a carefully engineered, fingernail-sized implant is the first to successfully eliminate tumors in mammals. The new approach, pioneered by bioengineers and ...
http://www.sciencedaily.com/releases/2009/11/091125145819.htm <http://www.sciencedaily.com/releases/2009/11/091125145819.htm>

Tailor-Made HIV/AIDS Treatment Closer to Reality <http://www.sciencedaily.com/releases/2009/11/091125110852.htm>
November 26, 2009
— An innovative treatment for HIV patients has passed its first clinical trial with flying colors. The new approach is an immunotherapy customized for each individual ...
http://www.sciencedaily.com/releases/2009/11/091125110852.htm <http://www.sciencedaily.com/releases/2009/11/091125110852.htm>

New Imagining Technique Could Lead to Better Antibiotics and Cancer Drugs <http://www.sciencedaily.com/releases/2009/11/091109174347.htm>
November 26, 2009
— A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer ...
http://www.sciencedaily.com/releases/2009/11/091109174347.htm <http://www.sciencedaily.com/releases/2009/11/091109174347.htm>

Alzheimer's: Destructive Amyloid-Beta Protein May Also Be Essential for Normal Brain Function <http://www.sciencedaily.com/releases/2009/11/091123114813.htm>
November 25, 2009
— Scientists have found that the amyloid-beta protein, currently the target of Alzheimer's drug research, is essential for normal information transfer through nerve cell networks in the brain. "If this ...
http://www.sciencedaily.com/releases/2009/11/091123114813.htm <http://www.sciencedaily.com/releases/2009/11/091123114813.htm>

Engineers and Doctors Develop Novel Material That Could Help Fight Arterial Disease <http://www.sciencedaily.com/releases/2009/11/091126083424.htm>
November 25, 2009
— Scientists are working to develop a device to treat peripheral arterial disease that could prevent thrombosis from occurring in small diameter ...
http://www.sciencedaily.com/releases/2009/11/091126083424.htm <http://www.sciencedaily.com/releases/2009/11/091126083424.htm>

Vioxx Trial Data Shows Early Cardiovascular Risk <http://www.sciencedaily.com/releases/2009/11/091123171412.htm>
November 24, 2009
— Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, ...
http://www.sciencedaily.com/releases/2009/11/091123171412.htm <http://www.sciencedaily.com/releases/2009/11/091123171412.htm>


Source - Health Day:


Health Highlights: Nov. 30, 2009 <http://www.healthday.com/Article.asp?AID=633532>
  • WHO Issues New HIV Treatment Recommendations
  • Kangaroo Enzyme May Hold Clues to Skin Cancer Prevention
  • Magnetized Discs Kill Cancer Cells: Study
Health Reform: What's in It for You?
Here's how the House and Senate bills stack up.
Clinical Trials Update: Nov. 25, 2009 <http://www.healthday.com/Article.asp?AID=633504>
  • Stress Urinary Incontinence
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rheumatoid Arthritis (RA)


Source - Yahoo Biotech News:


BioMarin treatment gets special FDA status <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/ap/091130/us_biomarin_fda.html?.v=1> - AP - Mon 9:27 am ET
BioMarin Pharmaceutical Inc. said Monday the Food and Drug Administration granted orphan drug designation to a developing treatment for a rare autoimmune disorder.

NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/prnews/091130/ph17896.html?.v=1> - PR Newswire - Mon 8:05 am ET
Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older .

New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents <http://us.rd.yahoo.com/finance/industry/news/mostpop/*http:/biz.yahoo.com/prnews/091130/sf17782.html?.v=1> - PR Newswire - Mon 1:30 am ET
Cell Therapeutics, Inc. announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.



Source - Google Health News:



Novartis inaugurates large-scale US based cell-culture influenza vaccine ... <http://www.google.com/url?sa=X&q=http://pr-canada.net/index.php%3Foption%3Dcom_content%26task%3Dview%26id%3D147233%26Itemid%3D61&ct=ga&cd=wiDjQ7jYBtc&usg=AFQjCNHjZXIj9g9ja4K4z6P00nrCDJ_RMQ>
PR-CANADA.net (press release)
MF59 has also been shown to provide cross-protection across similar strains of a H5N1 virus, which is an additional important element for a pre-pandemic ...

WHO concerned with new avian flu cases <http://www.google.com/url?sa=X&q=http://www.mb.com.ph/articles/231485/who-concerned-with-new-avian-flu-cases&ct=ga&cd=pa5GVjODxg0&usg=AFQjCNE2Q6VXxZEgVLALf0hfwIwyKpgn1g>
Manila Bulletin
By JENNY F. MANONGDO Experts from the World Health Organization are concerned over the new cases of Avian Influenza or the H5N1 in poultries in Egypt, ...
Is Gene-Therapy Medical Treatment Ready for Prime Time? <http://www.google.com/url?sa=X&q=http://www.time.com/time/health/article/0,8599,1942862,00.html%3Fxid%3Drss-topstories&ct=ga&cd=2_NgFmgZeO0&usg=AFQjCNFIsaj1A3xxIFtyopREOq-wmJOmkQ>
TIME
Then it seemed like simple fiction: while theoretically possible, gene therapy appeared unlikely to become a true therapeutic option, the field having ...

New therapy injects healthy genes to treat medical problems <http://www.google.com/url?sa=X&q=http://www.wndu.com/mmm/headlines/74021212.html&ct=ga&cd=YOS7Z8E0a10&usg=AFQjCNGnj6TgCAxy1_kISKjdgXfMMpBTpQ>
WNDU-TV
There are more than 1500 gene therapy trials going on around the world to treat everything from Parkinson's to blindness to clogged arteries. ...

Gene Therapy Repairs Damaged Lungs For Transplants <http://www.google.com/url?sa=X&q=http://www.redorbit.com/news/health/1777007/gene_therapy_repairs_damaged_lungs_for_transplants/&ct=ga&cd=uMDXSHUCNug&usg=AFQjCNGOUiHFlVYZBe4wu4EBlC6r9DMHRQ>
RedOrbit
Canadian researchers have successfully used gene therapy to repair injured human donor lungs, making them potentially suitable for transplantation into ...

Vaccine system remains antiquated <http://www.google.com/url?sa=X&q=http://www.washingtonpost.com/wp-dyn/content/article/2009/11/23/AR2009112302277.html%3Fhpid%3Dsec-health&ct=ga&cd=OXvF7CB4S18&usg=AFQjCNEpaXTq5Xleo03HDfwWmWyTRgb2OA>
Washington Post
If the next pandemic is caused by a virus that kills birds, like the H5N1 avian flu virus that emerged in 1997 in Hong Kong and reemerged in 2003, ...


Source - Medical News Today:



According To The Sage Group, Almost 3 Million People In India Suffer From Critical Limb Ischemia Caused By Atherosclerotic Peripheral Arterial Disease <http://www.medicalnewstoday.com/articles/172440.php>
A new analysis published by THE SAGE GROUP concludes that atherosclerotic peripheral arterial disease (PAD) afflicts over 20 million in India. Both PAD and CLI represent major and significantly underestimated problems for the Indian economy and healthcare system.
"Although it is commonly believed that PAD is a 'Western' disease with a lower prevalence in Asian Indians, our research indicates that this is not the case," stated Mary L. Yost, author of the report. "PAD appears to afflict Indians at similar rates as those found in European and U.S. populations in the same age and risk factor groups," she continued.

http://www.medicalnewstoday.com/articles/172440.php <http://www.medicalnewstoday.com/articles/172440.php>

Cancer In Europe: New Figures Show A Steady Decline In Mortality But Big Variations <http://www.medicalnewstoday.com/articles/172413.php>
New figures on deaths from
cancer <http://www.medicalnewstoday.com/info/cancer-oncology/whatiscancer.php> in Europe show a steady decline in mortality between the periods 1990-1994 and 2000-2004. Deaths from all cancers in the European Union (EU) between these two periods fell by nine percent in men and eight percent in women, with a large drop among the middle-aged population. In a study published online in the cancer journal, Annals of Oncology [1], researchers found that there was an average 185.2 deaths per 100,000 of the population per year in men between 1990-1994 in 27 member states of the EU, but this fell to 168 deaths per 100,000 between 2000-2004. For women, the number of deaths fell from 104.8 to 96.9 per 100,000.
http://www.medicalnewstoday.com/articles/172413.php <http://www.medicalnewstoday.com/articles/172413.php>

HIV/AIDS Treatment Specific To Each Patient Moves Closer To Reality <http://www.medicalnewstoday.com/articles/172298.php>
An innovative treatment for
HIV <http://www.medicalnewstoday.com/articles/17131.php> patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. Sékaly from the Université de Montréal. "This is a vaccine made for the individual patient - an "haute couture" therapy, instead of an off-the-rack treatment" said Dr Routy. By "priming" the immune system, as with a vaccine, to fight the specific strain of HIV/AIDS infecting a given patient, the scientists believe they have developed a therapy that shows immense promise and could be an even more effective weapon against the virus than the anti-retroviral cocktails currently in use. The results of the first-stage clinical trials, which tested the therapy in conjunction with anti-retroviral drugs, were published recently in Clinical Immunology. Phase 2 of the clinical trial, which is nearly complete, is testing the therapy's efficacy on its own at 8 different sites in Canada.
http://www.medicalnewstoday.com/articles/172298.php <http://www.medicalnewstoday.com/articles/172298.php>

Advanced Medical Imaging Techniques Utilized By Most Radiation Oncologists, Study Suggests <http://www.medicalnewstoday.com/articles/172095.php>
A recent study shows that 95 percent of radiation oncologists use advanced imaging techniques such as positron emission tomography (FDG-PET), magnetic resonance imaging (MRI), and 4-dimensional computed tomography (4DCT) for target delineation (to locate the tumor and other areas at risk for having
cancer <http://www.medicalnewstoday.com/info/cancer-oncology/whatiscancer.php> ), according to an article in the December issue of the Journal of the American College of Radiology, (JACR). In defining the target, the radiation oncologist draws upon a number of sources, including physical examination, operative and pathology reports, and knowledge of the patterns of tumor spread and failure. Imaging, however, is perhaps the single most important tool to guide target definition.
http://www.medicalnewstoday.com/articles/172095.php <http://www.medicalnewstoday.com/articles/172095.php>

Will Vaccines Change The Face Of Cancer Treatment? <http://www.medicalnewstoday.com/articles/172142.php>
The
H1N1 <http://www.medicalnewstoday.com/articles/147720.php> vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers <http://www.medicalnewstoday.com/info/cancer-oncology/whatiscancer.php> may be added to the list of diseases for which vaccinations will be employed. But this is not a new development. Such vaccines have rather quietly been in development for a decade and an array of products are poised to launch, according to "Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition," from healthcare market research publisher Kalorama Information. Following the first multi-billion dollar cancer vaccine blockbuster Gardasil <http://www.medilexicon.com/drugs/gardasil.php> , drug makers are taking notice, promising more cancer vaccines on the horizon against the likes of colorectal, lung, breast and prostate cancers <http://www.medicalnewstoday.com/articles/150086.php> . According to Kalorama, cancer vaccine sales will more than double from $1.8 billion in 2008 to $4.2 billion by 2012. This unprecedented growth is creating countless opportunities for market participants.
http://www.medicalnewstoday.com/articles/172142.php <http://www.medicalnewstoday.com/articles/172142.php>


Source - MIT's Technology Review:


Arming the Immune System against H1N1 <http://www.technologyreview.com/biomedicine/24001/>
http://www.technologyreview.com/biomedicine/24001/ <http://www.technologyreview.com/biomedicine/24001/>

A Cancer-Fighting Implant <http://www.technologyreview.com/biomedicine/24013/>
http://www.technologyreview.com/biomedicine/24013/ <http://www.technologyreview.com/biomedicine/24013/>

Identifying Anticancer Immune Cells <http://www.technologyreview.com/biomedicine/24020/>
http://www.technologyreview.com/biomedicine/24020/ <http://www.technologyreview.com/biomedicine/24020/>

Big Hope for Tiny Particles <http://www.technologyreview.com/biomedicine/24022/>
http://www.technologyreview.com/biomedicine/24022/ <http://www.technologyreview.com/biomedicine/24022/>

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.